Comparative study of the equivalence of the biosimilar follitropin alpha preparation (solution for subcutaneous injection) and the original follitropin alpha preparation (lyophilisate for preparation of solution for subcutaneous administration) in women with different responses to ovarian stimulation in an in vitro fertilization program: results of a phase IV clinical trial
- Authors: Perminova S.G.1, Nazarenko T.A.1, Korneeva I.E.1, Bashmakova N.V.2, Mityurina E.V.1, Alimova O.A.2, Belova I.S.1, Ershov A.V.2, Khramtsova A.Y.2, Dzhalilova E.R.2
-
Affiliations:
- Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
- Urals Research Institute of Maternity and Child Care, Ministry of Health of Russia
- Issue: No 10 (2022)
- Pages: 138-149
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249587
- DOI: https://doi.org/10.18565/aig.2022.10.138-149
- ID: 249587
Cite item
Abstract
Full Text
About the authors
Svetlana G. Perminova
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of RussiaDr. Med. Sci., Leading Researcher at Reproductology Department
Tatiana A. Nazarenko
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: t_nazarenko@oparina4.ru
Dr. Med. Sci., Professor, Director of the Institute of Reproductive Medicine
Irina E. Korneeva
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: irina.korneeva@inbox.ru
Dr. Med. Sci., Professor, Senior Researcher at the Scientific and Clinical Department of Assisted Reproductive Technology named after F. Paulsen
Nadezda V. Bashmakova
Urals Research Institute of Maternity and Child Care, Ministry of Health of RussiaDr. Med. Sci., Professor, Honored Doctor of the Russian Federation, Head of the Department of ART, Chief obstetrician-gynecologist of the Ural Federal District, Chief Researcher
Elena V. Mityurina
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: e_mityurina@oparina4.ru
PhD, Senior Researcher at Reproductology Department
Olga A. Alimova
Urals Research Institute of Maternity and Child Care, Ministry of Health of RussiaPhD, Reproductologist at the Department of Assisted Reproductive Technologies
Irina S. Belova
Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia
Email: irina-belova00@mail.ru
graduate student
Andrey V. Ershov
Urals Research Institute of Maternity and Child Care, Ministry of Health of RussiaJunior Researcher at the Department of Assisted Reproductive Technologies
Alexandra Yu. Khramtsova
Urals Research Institute of Maternity and Child Care, Ministry of Health of Russia
Email: aleksaxr@mail.ru
obstetrician-gynecologist, researcher, Department of ART
El’mira R. Dzhalilova
Urals Research Institute of Maternity and Child Care, Ministry of Health of Russia
Email: vip.dzhalilova20l7@mail.ru
obstetrician-gynecologist at the Department of Assisted Reproductive Technologies
References
- Lunenfeld B., Bilger W., Longobardi S., Alam V., D’Hooghe T., Sunkara S.K. The development of gonadotropins for clinical use in the treatment of infertility. Front. Endocrinol. (Lausanne). 2019; 10: 429. https://dx.doi.org/10.3389/fendo.2019.00429.
- European Medicines Agency. GONAL-f (follitropin alfa): summary of product characteristics. 2010. Available at: https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_en.pdf Accessed October 2020.
- Food and Drug Administration: GONAL-F® RFF* REDI-JECT™ (follitropin alfa): prescribing information. 2013. Available https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021684s036lbl.pdf Accessed October 2020.
- Drugs.com. Follistim AQ Approval History. 2018. Available at: https://www.drugs.com/history/follistim-aq.html Accessed March 26, 2019.
- Howles C.M. Genetic engineering of human FSH (Gonal-F). Hum. Reprod. Update.1996; 2(2): 172-91. https://dx.doi.org/10.1093/humupd/22.172.
- European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance:non-clinical and clinical issues. 2014. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-similar-biological-medicinalproducts-containing-biotechnology-derived-proteins-active_en-2.pdf Accessed October 2020.
- Velthuis E., Hubbard J., Longobardi S., D’Hooghe T. The frequency of ovarian Hyperstimulation syndrome and thromboembolism with originatorrecombinant human Follitropin Alfa (GONAL-f) for medically assisted reproduction: a systematic review. Adv. Ther. 2020; 37(12): 4831-47. https://dx.doi.org/10.1007/s12325-020-01512-w.
- Al-Inany H.G., Abou-Setta A.M., Aboulghar M.A., Mansour R.T., Serour G.I. Efficacy and safety of human menopausal gonadotrophins versus recombinant FSH:a meta-analysis. Reprod. Biomed. Online. 2008; 16 (1): 81-8. https://dx.doi.org/10.1016/s1472-6483(10)60559-7.
- Coomarasamy A., Afnan M., Cheema D., van der Veen F., Bossuyt P.M., vanWely M. Urinary hMG versus recombinant FSH for controlled ovarian hyperstimulation following an agonist long down-regulation protocol in IVFor ICSI treatment: a systematic review and meta-analysis. Hum. Reprod. 2008; 23(3): 10-5. https://dx.doi.org/10.1093/humrep/dem305.
- Budani M.C., Fensore S., Di Marzio M., Tiboni G.M. Efficacy and safety of follitropin alpha biosimilars compared to their reference product: a metaanalysis. Gynecol. Endocrinol. 2021; 37(5): 406-414. https://dx.doi.org/10.1080/09513590.2020.1792437.
- World Health Organization. Expert Committee on Biological Standardization. WHO Guidelines on evaluation of similar biotherapeutic products (SBPs). Geneva: WHO; 2009. Available at: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL_2010.pdf
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) EMA/CHMP/437/04 Guideline on similar biological medicinal products (Rev.1). 2014. Available at: https://www.ema.europa.eu/en/similar-biological-medicinal-products
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMEA/CHMP/BMWP/42832/2005 Rev1. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues; 2014b. Available at: https://www.ema.europa.eu/en/documents/scientificguideline/guideline-similar-biological-medicinal-products-containing-biotechnology-derived-proteins-active_en-2.pdf
- European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP) EMA/CHMP/41467/2013 Assessment report. Ovaleap. International non-proprietary name: follitropin alfa. 2013b. Available at: https://www.ema.europa.eu/en/documents/assessment-report/ovaleap-epar-public-assessment-report_en.pdf
- European Medicines Agency. Committee for Medicinal Products for Human Use. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human follicle stimulating hormone(r-hFSH). EMA/597110/2012., 2013. Available at: https://www.ema.europa.eu/documents/scientific-guideline/guideline-nonclinical-clinical-development-similar-biological-medicinal-productscontaining_en.pdf
- Министерство здравоохранения Российской Федерации. Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения». Руководство по экспертизе лекарственных средств. т. IV. М.; 2014.
- Подкорытов А.Б., Жиляев О.В., Ползиков М.А. Шприц-ручка для самостоятельного введения раствора фоллитропина альфа с минимальным шагом устанавливаемой дозы 5 МЕ. Акушерство, гинекология и репродукция. 2017; 11(4): 35-42. https://dx.doi.org/10.17749/2313-7347.2017.11.4.035-042.
- Vorob’ev 1.1., Khodak Y.A., Proskurina O.V., Gosudarev A.I., Semikhin A.S., Byrikhina D.V., et al. Physicochemical properties, toxicity, and specific activity of a follitropin alpha biosimilar. Pharm. Chem. J. 2017; 50(11): 753-60. https://dx.doi.org/10.1007/s11094-017-1525-3.
- Orlova N.A., Kovnir S.V., Khodak Y.A., Polzikov M.A., Nikitina V.A., Skryabin K.G., Vorobiev I.I. High-level expression of biologically active human follicle stimulating hormone in the Chinese hamster ovary cell line by a pair of tricistronic and monocistronic vectors. PLoS One. 2019; 14(7): e0219434. https://dx.doi.org/10.1371/journal.pone.0219434.
- Тюлькина Е.Е., Гордеев И.Г., Гребенкин Д.Ю., Казей В.А., Цикаришвили М.М., Лучинкина Е.Е., Абдулла Б.Х., Самандари С., Воробьев И. И., Шигабутдинов А.Ф., Ползиков М.А. Сравнительное рандомизированное перекрестное исследование переносимости и фармакокинетики препаратов Примапур® и Гонал-ф® при однократном подкожном введении здоровым добровольцам. Экспериментальная и клиническая фармакология. 2017; 80(4): 13-7. https://dx.doi.org/10.30906/0869-2092-2017-80-4-13-17.
- Барахоева З.Б., Вовк Л.А., Зорина И.В., Белоусова Н.Ю., Тетерина Т.А., Яковенко С.А., Апрышко В.П., Фетисова Ю.А., Марилова Н.А., Морозова Е.Г., Овчинникова М.М., Тищенко М.А., Щербатюк Ю.В., Колотовкина А.В., Мискун А.А., Касьянова Г.В., Сичинава Л.Г., Шалина Р.И., Ползиков М.А. Основные результаты сравнительного многоцентрового исследования III фазы биоаналогового фоллитропина альфа (Примапур®) и оригинального фоллитропина альфа (Гонал-ф®). Акушерство, гинекология и репродукция. 2018; 12(3): 5-16. https://dx.doi.org/10.17749/2313-7347.2018.12.3.005-016.
- Камилова Д.П., Овчинникова М.М., Абляева Э.Ш., Левиашвили М.М., Стулева Н.С., Бройтман Е.В., Ганихина М.А., Маясина Е.Н., Исхакова Л.Ф., Боярский К.Ю., Овсянникова Е.Н., Барахоева З.Б., Никитин С.В., Бендусов И.А., Фетисова Ю.А., Юдина М.А., Тарарашкина Е.С., Хетагурова Д.Т., Блинов Д.В., Ползиков М.А. Эффективность применения биоаналогового фоллитропина альфа в реальной клинической практике: результаты наблюдательного исследования «ФОЛЛИТРОПИН». Акушерство, гинекология и репродукция. 2021; 15(1): 5-21. https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2021.212.
- de Mora F., Howles C.M. Overlapping biosimilar and originator follitropin alfa preparations: How much closer can they get? Drug Discov. Today. 2022; 27(8): 2071-5. https://dx.doi.org/10.1016/j.drudis.2022.04.022.
- Barakhoeva Z., Vovk L., Fetisova Y., Marilova N., Ovchinnikova M., Tischenko M., Scherbatyuk Y., Kolotovkina A., Miskun A., Kasyanova G., Teterina T., Zorina I., Belousova N., Morozova E., Yakovenko S., Apryshko V., Sichinava L., Shalirn R., Polzikov M. A multicenter, randomized, phase III study comparing the efficacy and safety of follitropin alpha biosimilar and the original follitropin alpha. Eur. J. Obstet. Gynecol. Reprod. Biol. 2019; 241: 6-12. https://dx.doi.org/10.1016/j.ejogrb.2019.07.032.
- Longobardi S., Mol B., Chua S.J., Wang R., Venetis C., Papsch R. et al. A systematic review and meta-analysis, comparing biosimilar versus originator recombinant follitropin alfa in women undergoing IVF/ICSI’. Hum. Reprod. 2019; 34(Suppl. 1): 106.
- Strowitzki T., Kuczynski W., Mueller A., Bias P. Randomized, active-controlled, comparative phase 3 efficacy and safety equivalence trial of Ovaleap® (recombinant human follicle-stimulating hormone) in infertile women using assisted reproduction technology (ART). Reprod. Biol. Endocrinol. 2016; 14: 1. https://dx.doi.org/10.1186/s12958-015-0135-8.
- Rettenbacher M., Andersen A.N., Garcia-Velasco J.A., Sator M., Barri P., Lindenberg S. et al. A multi-centre phase 3 study comparing efficacy and safety of Bemfola((R)) versus Gonal-f((R)) in women undergoing ovarian stimulation for IVF. Reprod. Biomed. Online. 2015; 30(5): 504-13. https://dx.doi.org/10.1016/j.rbmo.2015.01.005.